Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139401 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | December 2020 | August 2022 | Abandon | 19 | 3 | 0 | Yes | No |
| 17134827 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | December 2020 | July 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17135528 | Treatment With Powdered Intranasal Epinephrine | December 2020 | May 2022 | Allow | 16 | 2 | 1 | Yes | No |
| 17132116 | LIQUID SULFONYLUREA-CONTAINING HERBICIDAL COMPOSITIONS | December 2020 | December 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 17130193 | FUNGICIDAL COMBINATIONS | December 2020 | April 2025 | Allow | 52 | 5 | 0 | Yes | No |
| 17129167 | EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE | December 2020 | October 2022 | Allow | 21 | 2 | 0 | No | No |
| 17128916 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | December 2020 | November 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17254446 | PLANT MATERIAL COATING AND PREPARATION PROCEDURE | December 2020 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17129004 | Methods and Compositions for Controlling Corn Rootworm | December 2020 | February 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17254209 | COMPOSITION AND METHOD FOR REDUCING SPRAY DRIFT | December 2020 | April 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17059614 | FLUTICASONE AND VILANTEROL FORMULATION AND INHALER | November 2020 | October 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17107478 | FORMULATION FOR TREATING CHRONIC WOUNDS | November 2020 | January 2024 | Abandon | 38 | 3 | 0 | No | No |
| 16950185 | RIBAVIRIN PERFLUBRON EMULSION COMPOSITION FOR TREATING VIRAL DISEASES | November 2020 | February 2023 | Abandon | 27 | 2 | 0 | Yes | No |
| 17054951 | MUTANTS OF PAENIBACILLUS AND METHODS FOR THEIR USE | November 2020 | August 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17053247 | COMBINATIONS OF ORGANIC COMPOUNDS TO INCREASE CROP PRODUCTION | November 2020 | August 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17087538 | MICROSPHERES FOR EXTENDED, CONTROLLED RELEASE OF THERAPEUTIC AGENTS | November 2020 | March 2025 | Allow | 53 | 3 | 2 | Yes | Yes |
| 17083989 | Systems, Methods and Products for Minimizing Tissue Reactions and Tissue Injury at an Infusion Site | October 2020 | August 2022 | Allow | 22 | 1 | 0 | No | No |
| 17078244 | STABLE SOLID HERBICIDE DELIVERY SYSTEMS | October 2020 | March 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17050348 | VIP and VIP Agonists, Nanoparticles, and Uses in Inflammatory T-Cell Mediated Disease | October 2020 | May 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17049099 | PHARMACEUTICAL COMPOSITION COMPRISING SALBUTAMOL | October 2020 | July 2024 | Abandon | 45 | 4 | 1 | No | No |
| 17047678 | COMPOSITIONS AND METHODS FOR ENHANCING ION TRANSPORTER ACTIVITY AND USES THEREOF | October 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17028630 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | September 2020 | March 2024 | Allow | 42 | 2 | 0 | Yes | Yes |
| 17026523 | ENGINEERED METAL NANOPARTICLES AND METHODS THEREOF | September 2020 | March 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17025851 | COATING FOR FLOWER HEADS | September 2020 | October 2024 | Abandon | 58 | 3 | 1 | No | No |
| 17024958 | CANNABINOID AND MENTHOL COMPOSITIONS AND METHODS | September 2020 | July 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16981615 | ACTIVATED FERRATE COMPOSITIONS | September 2020 | February 2025 | Allow | 53 | 5 | 1 | Yes | No |
| 17019740 | AEROSOL FORMULATION FOR COPD | September 2020 | October 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 16978512 | METHOD FOR IMPROVING SOLUBILITY OF SPARINGLY WATER-SOLUBLE COMPONENT | September 2020 | November 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16978652 | HIGH-LOAD GLYPHOSATE HERBICIDAL COMPOSITION, READY-TO-USE FORMULATION OBTAINED FROM THE COMPOSITION AND METHOD TO CONTROL VARIOUS WEED SPECIES IN AGRICULTURAL CROPS | September 2020 | January 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17007819 | BONDABLE MICROCAPSULES AND SURFACE FUNCTIONALIZED FILLERS | August 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 16971446 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | August 2020 | July 2023 | Allow | 35 | 3 | 1 | Yes | No |
| 16994425 | Diketopiperazine Microparticles with Defined Specific Surface Areas | August 2020 | January 2023 | Allow | 29 | 4 | 0 | No | No |
| 16989642 | PHARMACEUTICAL OIL-IN-WATER NANO-EMULSION | August 2020 | May 2022 | Allow | 21 | 1 | 1 | Yes | No |
| 16988459 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | August 2020 | January 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 16988470 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | August 2020 | January 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 16986804 | Non-Gelling Soluble Extracellular Matrix with Biological Activity | August 2020 | December 2022 | Abandon | 28 | 2 | 0 | Yes | No |
| 16944008 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | July 2020 | February 2022 | Allow | 19 | 1 | 0 | No | No |
| 16965095 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | July 2020 | May 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16936220 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS | July 2020 | November 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16933059 | FORMULATIONS FOR EYE TREATMENTS | July 2020 | February 2025 | Allow | 55 | 6 | 0 | No | No |
| 16926199 | USE OF NANOPARTICLES FOR TREATING RESPIRATORY INFECTIONS ASSOCIATED WITH CYSTIC FIBROSIS | July 2020 | September 2024 | Allow | 50 | 7 | 0 | Yes | No |
| 16759152 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR DEVELOPMENT, COMPRISING IRONE AS ACTIVE INGREDIENT | July 2020 | October 2021 | Allow | 18 | 1 | 0 | No | No |
| 16958965 | DRY POWDER KETAMINE COMPOSITION FOR USE IN THE TREATMENT OF DEPRESSION BY PULMONARY ADMINISTRATION | June 2020 | December 2024 | Abandon | 53 | 4 | 1 | Yes | No |
| 16914585 | 1-AMINO-1-CYCLOPROPANECARBOXYLIC ACID HYDROCHLORIDE FORMULATIONS | June 2020 | February 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 16901268 | Surfactant Formulations for Inhalation | June 2020 | June 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16895638 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | June 2020 | January 2023 | Allow | 32 | 3 | 1 | Yes | No |
| 16896007 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | June 2020 | October 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16888371 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | May 2020 | October 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16877047 | Coating a Respiratory System | May 2020 | January 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16874168 | NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | May 2020 | September 2024 | Abandon | 52 | 6 | 1 | No | No |
| 16864473 | Sprayable, Aqueous Alcoholic Microbicidal Compositions Comprising Zinc Ions | May 2020 | July 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16864035 | NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOF | April 2020 | September 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16861322 | SOIL METABOLIZABLE CYANAMIDE PESTICIDE COMPOSITIONS | April 2020 | December 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16843721 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | April 2020 | August 2020 | Allow | 5 | 1 | 0 | No | No |
| 16843759 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | April 2020 | January 2021 | Abandon | 9 | 1 | 0 | No | No |
| 16843579 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | April 2020 | January 2021 | Abandon | 9 | 1 | 0 | No | No |
| 16843810 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | April 2020 | February 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16843837 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | April 2020 | December 2021 | Allow | 20 | 2 | 0 | No | No |
| 16839305 | COMPOSITIONS CONTAINING BONE MORPHOGENIC PROTEINS AND METHODS THEROF | April 2020 | June 2025 | Abandon | 60 | 6 | 0 | No | No |
| 16652904 | INHALABLE COMPOSITION OF CLOFAZIMINE AND METHODS OF USE THEREOF | April 2020 | December 2023 | Abandon | 45 | 4 | 1 | Yes | No |
| 16650140 | COMPOSITION FOR PROMOTING ADIPOCYTE DIFFERENTIATION OR ADIPONECTIN, COMPRISING TRIMETHOXY PHENYL COMPOUND | March 2020 | January 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16648535 | POLYMERIC PARTICLES CONTAINING MICROORGANISMS | March 2020 | November 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16820436 | POST-EMERGENCE HERBICIDE | March 2020 | August 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16818755 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION | March 2020 | July 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16807229 | CANNABINOID AND MENTHOL GEL COMPOSITIONS, PATCHES AND METHODS | March 2020 | September 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16807256 | CANNABINOID, MENTHOL AND CAFFEINE DISSOLVABLE FILM COMPOSITIONS, DEVICES AND METHODS | March 2020 | September 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16806476 | CANNABINOID AND MENTHOL COMPOSITIONS AND METHODS | March 2020 | August 2020 | Allow | 5 | 1 | 0 | Yes | No |
| 16643198 | Use Of Inhaled Nitric Oxide For The Treatment Of Pulmonary Hypertension Associated With Lung Disease | February 2020 | May 2024 | Abandon | 50 | 4 | 0 | No | No |
| 16791431 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE | February 2020 | October 2021 | Abandon | 20 | 3 | 0 | Yes | No |
| 16773656 | DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS | January 2020 | December 2022 | Abandon | 35 | 2 | 0 | No | Yes |
| 16633911 | TOPICAL HERBAL COMPOSITIONS | January 2020 | August 2024 | Allow | 54 | 5 | 1 | Yes | No |
| 16461564 | ORAL COLON-TARGETED DELIVERY SYSTEM AND PREPARATION METHOD AND APPLICATION THEREOF | January 2020 | July 2023 | Allow | 50 | 4 | 1 | Yes | No |
| 16715332 | Inhalable Particles | December 2019 | February 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16695864 | PLANT VASCULAR DISEASE TREATMENT COMPOSITION | November 2019 | January 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16689611 | PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERS | November 2019 | August 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16681072 | HERBICIDAL COMBINATION | November 2019 | January 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16679033 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS | November 2019 | September 2020 | Abandon | 10 | 1 | 0 | No | No |
| 16676016 | COMPOSITIONS FOR TREATING PAIN AND INFLAMMATION | November 2019 | October 2022 | Abandon | 35 | 3 | 0 | No | No |
| 16594897 | MULTIMODAL PARTICULATE FORMULATIONS | October 2019 | November 2021 | Abandon | 25 | 1 | 0 | No | No |
| 16594602 | METHODS FOR INCREASING ORAL OSTEOGENESIS USING LIPOXIN A4 (LXA4) AND ITS ANALOGS | October 2019 | October 2023 | Allow | 48 | 5 | 0 | Yes | No |
| 16577416 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | September 2019 | July 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16577212 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | September 2019 | July 2021 | Allow | 22 | 1 | 0 | No | No |
| 16577312 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | September 2019 | July 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16565217 | PHARMACEUTICAL COMPOSITION | September 2019 | October 2022 | Abandon | 37 | 4 | 0 | Yes | No |
| 16565226 | PHARMACEUTICAL COMPOSITION | September 2019 | December 2022 | Abandon | 39 | 4 | 0 | Yes | No |
| 16558780 | CANNABINOID AND MENTHOL GEL COMPOSITIONS, PATCHES AND METHODS | September 2019 | June 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16558872 | CANNABINOID, MENTHOL AND CAFFEINE DISSOLVABLE FILM COMPOSITIONS, DEVICES AND METHODS | September 2019 | August 2021 | Allow | 23 | 1 | 0 | Yes | No |
| 16548062 | ANTIMICROBIAL SILVER IODATE | August 2019 | May 2021 | Allow | 21 | 1 | 0 | No | No |
| 16486596 | HYDROGEN SULFIDE AND/OR NITRITE IN THE TREATMENT AND PREVENTION OF ATRIAL FIBRILLATION | August 2019 | June 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16486682 | Chemical Composition | August 2019 | January 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16539149 | Low Dose Pharmaceutical Powders for Inhalation | August 2019 | June 2022 | Abandon | 34 | 1 | 0 | No | No |
| 16484656 | GASTROINTESTINAL RELEASE CAPSULE FOR USE IN A METHOD FOR DESENSITISING AND/OR INDUCING TOLERANCE IN A PATIENT WITH A PEANUT ALLERGY | August 2019 | September 2021 | Allow | 25 | 2 | 0 | No | No |
| 16482519 | HERBICIDAL COMBINATION | July 2019 | April 2022 | Allow | 32 | 4 | 0 | Yes | No |
| 16480806 | IMPROVED COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE | July 2019 | July 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16510846 | Drug Condensation Aerosols And Kits | July 2019 | March 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16477176 | IRON OXIDE/NANOKAOLIN COMPOSITE HEMOSTATIC AGENT AND PREPARATION METHOD THEREOF | July 2019 | June 2023 | Abandon | 48 | 4 | 1 | Yes | No |
| 16505133 | METHODS AND MATERIALS FOR TREATING LUNG DISORDERS | July 2019 | April 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16457746 | TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION | June 2019 | January 2020 | Allow | 7 | 0 | 0 | Yes | No |
| 16454353 | COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT | June 2019 | November 2020 | Allow | 16 | 0 | 0 | No | No |
| 16468621 | MIXTURES CONTAINING SECONDARY CALCIUM AND MAGNESIUM PHOSPHONATE AND THEIR USE AS FUNGICIDE OR FERTILIZER | June 2019 | May 2024 | Allow | 59 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAGHIGHATIAN, MINA.
With a 25.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HAGHIGHATIAN, MINA works in Art Unit 1616 and has examined 1,149 patent applications in our dataset. With an allowance rate of 51.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner HAGHIGHATIAN, MINA's allowance rate of 51.8% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAGHIGHATIAN, MINA receive 2.42 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAGHIGHATIAN, MINA is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +23.4% benefit to allowance rate for applications examined by HAGHIGHATIAN, MINA. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.9% of applications are subsequently allowed. This success rate is in the 21% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 32.9% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 54.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 54.7% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 71.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 52.4% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 9.0% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.